Asia & Emerging Markets
More efficient healthcare systems and treatments are needed and not only in industrialized countries. Emerging market countries are clearly gaining in importance, both as target markets and as centers of innovation. This is particularly true in Asia. A quarter of the estimated 400 million people worldwide who have diabetes are in China and almost a fifth live in ASEAN nations such as Malaysia or Thailand. Meanwhile population aging is increasing the number of cases of cancer, neurological and circulatory disease in these countries. Their national health systems face a steady increase in costs.
Taking China as an example
The healthcare industry is in a state of flux worldwide. This is also true for one of the largest drug markets in the world: China. In the Middle Kingdom, the cost of healthcare is still low – unlike in many Western nations (see table) – and that is one reason why China's healthcare policymakers can focus on making the country’s healthcare system more efficient and on creating or expanding of its own hubs of medical innovation. They are doing so by rewarding medical innovation with financial incentives.
Chinese officials also want to give a greater share of the population affordable access to healthcare. Lowering the price of generics and biosimilars plays a key role in the government's efforts to keep costs from spiraling out of control. Progress is also being made in expanding its in-country research and development capabilities and capacity as well as its production output of domestically developed medicines.
This is all part of a long-term plan under which the Chinese government is providing huge support in the form of tax and other financial incentives to establish and grow an internationally competitive biopharmaceutical industry of its own. The main pillars of the government's concept here are three large hubs of innovation – the Zhangjiang Hi-tech Park near Shanghai, BioBay in Suzhou and the Shenzhen innovation hub, which is often referred to as "China's Silicon Valley” because it is home to global companies such as Huawei.
Our Healthcare Team consists of an interdisciplinary mix of experts with many years of experience in the fields of biotechnology, medical technology and generics. Many of our experts are graduate biochemists or natural scientists with further economic training. The experienced team analyses a global universe of 600 listed healthcare companies by means of fundamental analysis using various quantitative and qualitative parameters. An important part of the research is regular company visits and participation in technical and financial conferences.
Team Healthcare Asia/Emerging Markets
Oliver Kubli, CFA, Lead Portfolio Manager
- Since 2015 Managing Director, Head Portfolio Management Healthcare Funds & Mandates
- 2008 – 2014 Member of the Management Team and Head Portfolio Management at Adamant Biomedical Investment AG
- 2000 – 2007 Senior Portfolio Manager at Zürcher Kantonalbank
- Bachelor of Business Administration, University of Applied Sciences, Winterthur, CFA
Dr. Cyrill Zimmermann, Portfolio Manager
- Since 2015 Head Healthcare Funds & Mandates, Member of the Executive Board
- 2001 – 2014 Co-founder and CEO of Adamant Biomedical Investment AG
- 1996 – 2000 Member of the Management Team BB Medtech at Bellevue Asset Management AG
- 1993 – 1996 Advisor for institutional clients and former assistant to the Executive Management at Credit Suisse
- Dr.oec.publ. (University of Zurich)
Remo Krauer, CIIA, Portfolio Manager
- Since 2018 Senior Portfolio Manager Healthcare Funds & Mandates
- 2016 -2018 Head Portfolio Construction, Discretionary Mandates at Zürcher Kantonalbank
- 2005 – 2016 Senior Portfoliomanager at Zürcher Kantonalbank
- Bachelor of Business Administration, University of Applied Sciences, Winterthur, CIIA
Our investment solutions
Bellevue Asset Management’s range of healthcare sector investment products is the broadest in Europe and, with the investment company BB Biotech, it has been an active and widely recognized investor in this sector for more than 20 years. The Healthcare Index created by Adamant in 2007 reflects the findings of its fundamental research. It is composed of the 40 most attractive healthcare stocks worldwide and is recalibrated every six months.
BB Adamant Asia Pacific Healthcare (Lux)
Show all share classes
BB Adamant Emerging Markets Healthcare (Lux)
Show all share classes
Markets & Opinions / 21.10.2020
Recording of the update call with the portfolio manager Remo Krauer and Oliver Kubli on October 21.
Markets & Opinions / 30.09.2020
Read the current issue of the Healthcare Observer.
Markets & Opinions / 02.09.2020
Recording of the update call with the Portfolio Manager Marcel Fritsch and Stefan Blum on September 3.
Markets & Opinions / 17.08.2020
Commentary by Portfolio Manager Stefan Blum about Teladoc Health’s takeover of Livongo.
Markets & Opinions / 09.07.2020
Update Call with Dr. Cyrill Zimmermann, Head Healthcare Funds & Mandates, on.July 8.
Markets & Opinions / 23.06.2020
Recording of the update call with Dr. Christian Lach about the biotech sector.
Markets & Opinions / 10.06.2020
Recording of the update call with the Portfolio Managers Oliver Kubli and Remo Krauer on June 10.
Markets & Opinions / 27.05.2020
Recording of the update call with Portfolio Manager Zahide Donat on May 27.
Markets & Opinions / 27.05.2020
Commentary by Stefan Blum and Marcel Fritsch, Portfolio Managers of the BB Adamant Medtech & Services Fund
Markets & Opinions / 26.05.2020
Read the current issue with focus on the corona virus.